CLEC2D hFc Chimera, Avi, Human
CLEC2D HFc Chimera, Avi, Human

The purity of CLEC2D hFc Chimera, Avi, Human is greater than 95% as determined by SEC-HPLC.

CLEC2D HFc Chimera, Avi, Human

CLEC2D hFc Chimera, Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

CLEC2D hFc Chimera, Avi, Human

C-type lectin domain family 2, member D (CLEC2D) is implicated in the immune response. Pre-eclampsia and HIV infection have opposing immune responses. The contrasting expression of CLEC2D in HIV infection and pre-eclampsia is demonstrative of the immunosuppressive and pro-inflammatory roles of the respective pathologies. However, this implication may be confounded by highly active anti-retroviral treatment (HAART).
Z05176
¥80,213.00

Ask us a question
Product Introduction
Species Human
Protein Construction
Avi hFc CLEC2D (Arg60-Val191)
Accession # Q9UHP7-1
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE
Endotoxin Level Less than 1EU per μg by the LAL method.
Expression System HEK293
Theoretical Molecular Weight 59.1 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 72-78 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • CLEC2D HFc Chimera, Avi, Human
    • CLEC2D HFc Chimera, Avi, Human

    The purity of CLEC2D hFc Chimera, Avi, Human is greater than 95% as determined by SEC-HPLC.

  • CLEC2D HFc Chimera, Avi, Human
    • CLEC2D HFc Chimera, Avi, Human

    CLEC2D hFc Chimera, Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background C-type lectin domain family 2, member D (CLEC2D) is implicated in the immune response. Pre-eclampsia and HIV infection have opposing immune responses. The contrasting expression of CLEC2D in HIV infection and pre-eclampsia is demonstrative of the immunosuppressive and pro-inflammatory roles of the respective pathologies. However, this implication may be confounded by highly active anti-retroviral treatment (HAART).
Synonyms C-type lectin domain family 2 member D;Lectin-like NK cell receptor;Lectin-like transcript 1;LLT-1;CLAX;LLT1;OCIL;CLEC2D

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.